

**Table 9.6h**  
**Persistency of Discharge Regimen by Follow-up Period, 2002 to 2006**  
**Recipients with Liver Transplants**

	Year of Transplant				
	2002	2003	2004	2005	2006
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
<b>CyA+Aza</b>					
At Discharge (N)	64	28	57	14	5
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	26.6%	17.9%	43.9%	35.7%	60.0%
1 Year PostTx (%)	12.5%	7.1%	28.1%	7.1%	60.0%
2 Years PostTx (%)	6.3%	3.6%	18.0%	7.1%	-
3 Years PostTx (%)	4.7%	3.6%	18.0%	7.1%	-
<b>CyA+MMF</b>					
At Discharge (N)	228	214	232	215	241
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	57.5%	57.9%	66.0%	73.6%	76.8%
1 Year PostTx (%)	35.4%	39.2%	49.9%	62.1%	58.1%
2 Years PostTx (%)	22.4%	28.9%	41.4%	52.8%	42.2%
3 Years PostTx (%)	20.0%	26.8%	33.8%	52.8%	-
<b>CyA+Siro</b>					
At Discharge (N)	29	26	27	34	42
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	37.9%	56.0%	66.7%	58.8%	57.1%
1 Year PostTx (%)	24.1%	36.0%	27.5%	52.8%	29.9%
2 Years PostTx (%)	17.2%	24.0%	15.7%	36.5%	29.9%
3 Years PostTx (%)	6.9%	9.6%	-	-	-
<b>Siro+MMF</b>					
At Discharge (N)	50	48	46	51	49
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	56.0%	64.6%	60.1%	78.0%	62.7%
1 Year PostTx (%)	29.1%	47.9%	35.6%	65.7%	48.1%
2 Years PostTx (%)	25.0%	39.0%	28.0%	49.6%	48.1%
3 Years PostTx (%)	22.9%	34.4%	24.0%	-	-
<b>Tac+Aza</b>					
At Discharge (N)	96	105	52	23	14
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	48.4%	50.5%	51.9%	69.6%	53.8%
1 Year PostTx (%)	33.4%	40.6%	36.5%	41.7%	53.8%
2 Years PostTx (%)	26.9%	30.5%	30.8%	41.7%	-
3 Years PostTx (%)	18.3%	27.2%	19.1%	-	-
<b>Tac+MMF</b>					
At Discharge (N)	1,864	2,347	2,669	3,098	3,701
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	67.3%	68.4%	72.2%	79.6%	82.8%

(Continued)

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

**Table 9.6h (Continued)**  
**Persistency of Discharge Regimen by Follow-up Period, 2002 to 2006**  
**Recipients with Liver Transplants**

	Year of Transplant				
	2002	2003	2004	2005	2006
<b>Discharge Regimen (w/ or w/o Steroid Use)</b>					
Tac+MMF					
1 Year PostTx (%)	50.3%	52.9%	57.8%	67.9%	71.6%
2 Years PostTx (%)	37.1%	41.9%	48.2%	59.8%	58.4%
3 Years PostTx (%)	30.9%	36.8%	43.5%	54.2%	-
Tac+Siro					
At Discharge (N)	142	62	102	61	72
At Discharge (%)	100.0%	100.0%	100.0%	100.0%	100.0%
6 Months PostTx (%)	65.0%	45.2%	61.8%	71.2%	72.9%
1 Year PostTx (%)	47.7%	33.5%	40.7%	56.0%	57.6%
2 Years PostTx (%)	34.7%	28.5%	39.7%	49.1%	28.8%
3 Years PostTx (%)	26.7%	25.1%	28.5%	49.1%	-

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.